Abstract 1236: Insight into genetic susceptibility to <i>BRCA</i>-negative male breast cancer by multigene panel testing: Results from a multicenter study in Italy
Piera Rizzolo(Sapienza University of Rome), Laura Ottini(Mount Sinai Hospital), Marco Montagna(Azienda Ospedale - Università Padova), Liliana Varesco(Istituti di Ricovero e Cura a Carattere Scientifico), Antonio Russo(Health Protection Agency), Laura Cortesi(Azienda Ospedaliero-Universitaria di Modena), Domenico Palli(Piedmont Reference Center for Epidemiology and Cancer Prevention), Valentina Silvestri(Cancer Research UK Cambridge Center), Virginia Valentini(Sapienza University of Rome), Daniele Calistri(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Alessandro Spinelli(IRCCS Materno Infantile Burlo Garofolo), Paolo Peterlongo(IFOM), Alessandra Viel(Centro di Riferimento Oncologico), Paolo Radice(IFOM), Giuseppe Giannini(Istituto Pasteur), Maria Grazia Tibiletti(University of Insubria), Veronica Zelli(University of L'Aquila)
Cited by 1
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Meat, Fish, and Colorectal Cancer Risk: The European Prospective Investigation into Cancer and Nutrition
|JNCI Journal of the National Cancer Institute|2005|865
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database
|Genetics in Medicine|2019|666
Body size and breast cancer risk: Findings from the European prospective investigation into cancer and nutrition (EPIC)
|International Journal of Cancer|2004|580